Publikationen in Zusammenarbeit mit Forschern von Sociedad Española de Reumatología (32)

2024

  1. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

    RMD open, Vol. 10, Núm. 2

2023

  1. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 137-144

  2. Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Characteristics associated with the perception of high-impact disease (PsAID ≥4) in patients with recent-onset psoriatic arthritis. Machine learning-based model

    Seminars in Arthritis and Rheumatism, Vol. 57

  2. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning

    Arthritis research & therapy, Vol. 24, Núm. 1, pp. 153

  3. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning

    Frontiers in Medicine, Vol. 9

2021

  1. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

2020

  1. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)

    Lupus, Vol. 29, Núm. 1, pp. 27-36

  2. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224

2019

  1. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

  2. Objectives and methodology of BIOBADASER phase III

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236

  3. SER recommendations on the use of biological drugs in primary Sjögren's syndrome

    Reumatologia Clinica, Vol. 15, Núm. 6, pp. 315-326

  4. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

2018

  1. Primary respiratory disease in patients with systemic lupus erythematosus: Data from the Spanish rheumatology society lupus registry (RELESSER) cohort

    Arthritis Research and Therapy, Vol. 20, Núm. 1

  2. Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis

    Reumatologia Clinica, Vol. 14, Núm. 5, pp. 254-268

  3. Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis

    Rheumatology International, Vol. 38, Núm. 4, pp. 589-598

2017

  1. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

  2. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 1, pp. 38-45

  3. Juvenile- and adult-onset systemic lupus erythematosus: A comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 6, pp. 1047-1055

  4. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3